KDR and non-small cell lung carcinoma: Our pooled results with the largest sample size demonstrate that the use of anti-VEGFR agents in advanced NSCLC significantly increase the risk of FAEs (RR 1.33, 95% CI 1.12–1.58, P = 0.001).